Table 3.
Efficacy outcomes for the use of IO as maintenance treatment for upper GI carcinomas compared with standard chemotherapy alonea
| Setting | No. of studies | Study | Investigational agent | Overall survival |
PFS |
Response rate |
|||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P b | HR (95% CI) | P b | OR (95% CI) | P b | ||||
| All studies | 3 | Bang et al., 2017c | Ipilinumab | 1.11 (0.68 to 1.80) | − | 1.59 (0.90 to 2.81)d | − | 0.24 (0.03 to 2.19) | − |
| JAVELIN-100 | Avelumab | 0.91 (0.74 to 1.13) | − | 1.04 (0.86 to 1.27) | − | 0.91 (0.55 to 1.51) | − | ||
| PLATFORM | Durvalumab | 0.92 (0.68 to 1.29) | − | 0.79 (0.59 to 1.06) | − | − | − | ||
| Pooled evidence | Any agent | 0.94 (0.79 to 1.11) | .46 | 1.02 (0.59 to 1.06) | .92 | 0.83 (0.51 to 1.36) | .47 | ||
| Any PD-L1 status | 2 | Pooled evidence | Any agent | 0.94 (0.77 to 1.15) | .55 | 1.09 (0.90 to 1.31) | .37 | 0.83 (0.51 to 1.36) | .47 |
| PD-L1 CPS > 1% | 1 | JAVELIN-100 | Avelumab | 1.13 (0.57 to 2.23) | − | 1.04 (0.53 to 2.02) | − | 0.91 (0.55 to 1.51) | − |
Only data for adenocarcinoma were available for analysis. CI = confidence interval; CPS = combined positive score; GI = gastrointestinal; HR = hazard ratio; IO = immunotherapy; OR = odds ratio; PD-L1 = programmed cell death ligand-1; PFS = progression-free survival.
Inverse-Variance and the Mantel-Haenszel statistical methods were applied for calculation of pooled hazard ratios and odds ratios, respectively. A 2-sided P value less than .05 was considered statistically significant.
Confidence interval for the hazard ratio was 92% in the original manuscript, recalculated to the 95% confidence interval for present comparisons.
Confidence interval for the hazard ratio was 80% in the original manuscript, recalculated as the 95% confidence interval for present comparisons.